PROFILPELAJAR.COM

罗非昔布
臨床資料
懷孕分級	澳: C ; ;
给药途径	口服
ATC碼	M01AH02 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 亦被撤回;
藥物動力學數據
生物利用度	93%
血漿蛋白結合率	87%
药物代谢	hepatic
生物半衰期	17 hours
排泄途徑	biliary/renal
识别信息
	IUPAC命名法 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; ;
CAS号	162011-90-7
PubChem CID	5090;
DrugBank	DB00533 ;
ChemSpider	4911 ;
UNII	0QTW8Z7MCR;
KEGG	D00568 ;
ChEBI	CHEBI:8887 ;
ChEMBL	ChEMBL122 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID2023567 ;
ECHA InfoCard	100.230.077
化学信息
化学式	C17H14O4S
摩尔质量	314.36 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES O=C2OCC(=C2\c1ccccc1)\c3ccc(cc3)S(=O)(=O)C;
	InChI InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3 ; Key:RZJQGNCSTQAWON-UHFFFAOYSA-N ;

罗非昔布或罗非考昔（英語：Rofecoxib，/ˌrɒfɪˈkɒksɪb/）商品名Vioxx、Ceoxx和Ceeoxx。是一种非甾体类抗炎药（NSAID），由默克公司製造、出售。美国食品药品监督管理局（FDA）于1999年5月20日批准上市，用以治疗骨关节炎、急性疼痛和痛经。

由於發現到長期且高劑量用藥有增加心臟病的風險^[1]^[2]，默克公司於2004年9月30日起從市場撤回此藥。

合成

注脚

^ 偉克適致死藥廠賠10億. [2017-02-26]. （原始内容存档于2017-09-12）.
^ 食品藥物釣愚：《釣愚：操縱與欺騙的經濟學》選摘（3）-食安｜藥物｜釣愚：操縱與欺騙的經濟學-風傳媒-喬治．艾克羅夫, 羅伯．席勒. [2017-02-26]. （原始内容存档于2017-04-23）.
^ Vioxxlawyer.org. Vioxxlawyer.org. [4 January 2015]. （原始内容存档于2015年1月5日）.

参考文献

FDA (2005). "Summary minutes for the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee." Published on the internet, March 2005. Link （页面存档备份，存于互联网档案馆）
Fitzgerald GA, Coxibs and Cardiovascular Disease, N Engl J Med 2004;351(17): 1709–1711. PMID 15470192.
Grassley CE (15 Oct 2004). Grassley questions Merck about communication with the FDA on Vioxx. Press Release.
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (published online; see also Merck response below)
Karha J and Topol EJ. The sad story of Vioxx, and what we should learn from it （页面存档备份，存于互联网档案馆） Cleve Clin J Med 2004; 71(12):933-939. PMID 15641522
Michaels, D. (June 2005) DOUBT Is Their Product Archive.is的存檔，存档日期2006-03-21, Scientific American, 292 (6).
Merck & Co., (5 Nov 2004). Response to Article by Juni et al. Published in The Lancet on Nov. 5. Press Release.
Merck & Co (30 Sep 2004) Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Press release [1].
D. M. Mukherjee, S. E. Nissen, and E. J. Topol, "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 186 (2001): 954–959.
Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352(11):1081-91. PMID 15713945
Okie, S (2005) "Raising the safety bar--the FDA's coxib meeting." N Engl J Med. 2005 Mar 31;352(13):1283-5. PMID 15800221.
Leleti Rajender Reddy, Corey EJ. Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to chronic human toxicity Tetrahedron Lett 2005, 46: 927. doi:10.1016/j.tetlet.2004.12.055
Swan SK et al., Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet. Annals of Int Med 2000; 133:1–9
Targum, SL. (1 Feb. 2001) Review of cardiovascular safety database. FDA memorandum. [2] （页面存档备份，存于互联网档案馆）
Wolfe, MM et al., Gastrointestinal Toxicity of Nonsteroidal Anti-anflamattory Drugs, New England Journal of Medicine. 1999; 340; 1888-98.